• Mashup Score: 2

    Malignancy is a leading cause of death in adults with congenital heart disease (ACHD). Cancer incidence in ACHD is approximately double that of the general population and is diagnosed earlier in life. Arrhythmia and baseline diuretic requirement predict morbidity and mortality in ACHD and cancer and represent potentially actionable venues to improve outcom es. Cancer screening must be emphasized in ACHD, and disease-specific cancer screening protocols are in dire need of development. Despite ongoing

    Tweet Tweets with this article
    • Malignancy is a major driver of mortality & morbidity in patients w/ #ACHD. The factors influencing cancer risk in this population are complex & likely interconnected. Explore further insights in this expert analysis on malignancy in ACHD: https://t.co/BvfdTj8eUZ #CardioX https://t.co/h9LDEiVFV5

  • Mashup Score: 0

    Meeting Type: Live Meetings Location: Virtually and Heart House, Washington, DC Join card io-obstetrics experts, including Course Chair Natalie Bello, MD, MPH, FACC and Course Vice Chair Deirdre J. Mattina, MD, FACC, in Washington, DC or virtually on Oct. 17 – 19, 2025 for Cardio-Obstetrics Essentials: Team-Based Management of Cardiovascular Disease and Pregnancy. CV disease is the leading cause of maternal mortality in the United States and due to the burden of pre-existing CV disease and risk factors

    Tweet Tweets with this article
    • Registration is now open for #ACCCardioOB! This interprofessional course focuses on the evolving field of #CardioObstetrics to ensure better diagnosis & treatment of your patients of child-bearing age. Learn more ➡️ https://t.co/eUJZfzoRyI @nataliebello9 @drladyheart https://t.co/EUmlZmBPcn

  • Mashup Score: 8

    Among persons with chronic kidney disease (CKD) and type 2 diabetes (T2D), combination therapy with finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio (UACR) than either drug alone, according to results from the CONFIDENCE trial published June 5 in the New England Journal of Medicine. In this double-blind multicenter trial, Rajiv Agarwal, MD, FACC, et al., randomized 800 patients (mean age 66 years, 25% women) to receive 10 or 20 mg of finerenon e once

    Tweet Tweets with this article
    • CONFIDENCE trial results: Among persons w/ chronic kidney disease & type 2 diabetes, combination therapy w/ finerenone ➕ empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Learn more: https://t.co/kvUbR2tT3H #CardioX

  • Mashup Score: 16

    The ACC’s Leadership Accelerator is a high-impact, immersive leadership development program designed specifically for ACC early-career members (defined as within seven years of CV fellowship).

    Tweet Tweets with this article
    • Looking for #ACCLeadership opportunities as an #ACCEarlyCareer member? Learn how Leadership Accelerator can help develop and strengthen your skills in its nine-month long, high-impact program. Applications are open now through June 19. 🔗 https://t.co/Z9a3UYegJz https://t.co/tIKRW4ytJL

  • Mashup Score: 9

    The SMART-CHOICE 3 trial demonstrated that clopidogrel monotherapy is more effective than aspirin monotherapy in reducing the risk of major adverse cardiac and cerebrovascular events in high-risk patients who completed standard dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). Despite concerns that more potent antiplatelet agents may increase bleeding risk, the study found that clopidogrel significantly reduced ischemic events—including myocardial infarction and all-cause

    Tweet Tweets with this article
    • 🎧 #ACCEL Lite: In this episode, Drs. @TaylorMHVIcard & Joo-Yong Hahn discuss the clinical implications of the SMART-CHOICE 3 trial findings & offer insights into selecting the optimal single antiplatelet regimen after #PCI. Tune in here: https://t.co/W5Av7OlfBQ #ACC25 https://t.co/fLO7CU4y89

  • Mashup Score: 5

    Learn best practices and emerging science across practice-changing topics in care including heart failure and cardiomyopathies, prevention and health promotion, and special topics. Join leading experts in the field for this series of interactive sessions to ensure you are up to date on the safety and efficacy of the newest therapies, and cultivate your skills in applying the latest clinical information into patient care. Learn to identify the disparities in hypertension management and the importance of

    Tweet Tweets with this article
    • Join leading experts in the field for the Clinical Spotlight Series – a series of interactive sessions from #ACC24 – & earn up to 4.5 CME/CNE credits & MOC points! Sessions include Hypertension Management; Iron Deficiency in Heart Failure Patients; & more. https://t.co/HnN4LhHGSs https://t.co/dufstpPGgc

  • Mashup Score: 12

    The purpose of our work group is to promote inclusion and equity within cardiology and to engage with clinicians to increase education to our cardiology colleagues about awareness of cardiovascular issues within the LGBTQ+ patient population as well as increasing visibility among our LGBTQ+ peers and creating a safe space within the College.

    Tweet Tweets with this article
    • ACC is celebrating #PrideMonth ❤️🧡💛💚💙💜 Did you know that we have an LGBTQ+ Work Group? Join us in sharing education, content, experiences, perspectives ➕ more using #ACCPride. Get involved here ➡️ https://t.co/dWKvw3mV5c #ACCHealthEquity @matthewcarazo https://t.co/1wZnYaBVCg

  • Mashup Score: 3

    The Rural Cardiovascular Health Initiative (RCHI) is a collaboration between the American College of Cardiology and the JF Maddox Foundation, to improve cardiovascular outcomes in the rural communities of Hobbs and Lovington in Lea County, NM.

    Tweet Tweets with this article
    • This week, community care partners from the Rural Cardiovascular Health Initiative (RCHI) are providing tips 📝 on how to lead a more heart healthy lifestyle through interactive and educational sessions. Learn more here ➡️ https://t.co/B4kEwIH8q0 @jf_maddox #healthequity https://t.co/afw9ZoUJIl

  • Mashup Score: 9

    Catheter ablation as a first-line strategy for ventricular tachycardia (VT) in patients with ischemic cardiomyopathy reduces the composite endpoint of death or serious arrhythmia outcomes compared with antiarrhythmic drugs (AADs). Catheter ablation was associated with fewer treated sustained VTs below the detection rate versus AADs. How does the efficacy and safety of catheter ablation as first-line therapy compare with antiarrhythmic drug (AAD) therapy for ventricular tachycardia (VT) in patients with

    Tweet Tweets with this article
    • Catheter ablation as a first-line treatment for VT in patients with ICM reduces the risk of recurrent VT episodes requiring #epICD shock or medical intervention compared with AAD therapy. Read more: https://t.co/wIhFpTIvBm #cvEP